Chronic kidney disease
Conditions
Interventions
Stem Cell Exosomes Treatment Group 1:receive treatment with 1×10^10 particles of exosomes via intravenous infusion
Stem Cell Exosomes Treatment Group 2:receive treatment with 2×10^10 particles of exosomes via intravenous infusion
Conventional treatment group:receive medications for conventional treatment of chronic kidney disease
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Include hospitalized patients with CKD stage 2-4, specifically those with 15 < GFR <= 60 ml/min/1.73 m^2, from the Affiliated Hospital of Xuzhou Medical University between July 2025 and July 2027; 2. Conduct tests on all included patients for kidney function and other laboratory indicators, as well as kidney biopsies for those without obvious kidney atrophy; 3. Require that included patients avoid reversible factors that may promote kidney function deterioration before the study, such as hypovolemia, acute stress states, and poor blood pressure control; 4. All patients had not undergone hemodialysis or peritoneal dialysis treatment prior to the study.
Exclusion criteria
Exclusion criteria: 1. Poor blood sugar control; 2. Complicated by severe metabolic acidosis, electrolyte disorders, severe cardiovascular and cerebrovascular diseases, severe acute pancreatitis, shock, dehydration, undergoing surgical treatment, and those with indications for emergency dialysis; 3. Patients with hyperthyroidism or those taking corticosteroids; 4. Complicated by malignant tumors, respiratory diseases affecting oxygen levels, cardiovascular diseases, hematological diseases, or other severe systemic diseases; 5. Individuals who may undergo kidney transplantation during the study period; 6. Expected survival time < 12 months; 7. Pregnant or breastfeeding women; 8. Patients who participated in other drug clinical trials within 3 months prior to enrollment;9. Patients who cannot cooperate due to poor mental status or who are assessed as ineligible by clinicians for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Renal function indicators of CKD patients after treatment with hUC-MSCs-exo; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients' kidney biopsies showed the degree of renal pathological damage after treatment with hUC-MSCs-exo.;Renal blood perfusion; | — |
Countries
China
Contacts
Public ContactSun Dong
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed